Background {#Sec1}
==========

Esophageal carcinoma (EC) is one of the major cancers in China \[[@CR1], [@CR2]\]. Environmental factors and life styles of esophageal carcinoma patients have been widely researched \[[@CR3]--[@CR5]\], although the pathogeny of esophageal cancer has not yet been determined. In 1982, Syrjanen first hypothesized the relationship between human papillomaviruses (HPV) infection and the development of esophageal cancer \[[@CR6]\]. Since then, many reports in the field have supported this viewpoint \[[@CR7]--[@CR13]\]. Our previous work showed that high-risk HPV types 16 and 18 were detected in esophageal tumors \[[@CR14]\], and HPV18 was localized in human chromosome 8 in the EC109 cell line \[[@CR15]\], these results indicates that HPV infection is a pathogenic factor for esophageal cancer.

Few studies have described the HPV integration site, so the objective of the current work to discuss HPV16 infection and integration site in the human genome to better understand its role in esophageal cancer. HPV infection detected using My09/11 for HPV L1 (16), HPV16 was determined using type-specific primer sets for HPV16 E6, and integration site of HPV16 in esophageal cancer was analyzed by amplification of papillomavirus oncogene transcripts (APOT), which allowed the discrimination of HPV mRNAs derived from integrated genomes \[[@CR17]\]. The integration of HPV in the host chromosome integration site can be accurately located by detection of the transcription of poly (A) tail \[[@CR18], [@CR19]\]. Namely, first, cDNA was synthesized by reverse transcription using RNA as template, and (dT)~17~-p3 as primer; second, PCR amplification was conducted using cDNA as template, p1-HPV16 E7 and p3 as primers; third, PCR was conducted using above PCR product as template, p2-HPV16 E7 and (dT)~17~-p3 as primers; fourth, the PCR product was cloned into a pMD-18 T vector; fifth, sequencing analysis and blast in GenBank. The integration sites was determined by sequence alignment including both HPV and human chromosome sequence.

Materials {#Sec2}
=========

Sample collection and preparation {#Sec3}
---------------------------------

A total of 189 fresh surgically resected tissue samples and clinical information of patients were obtained in 2013.03 to 2015.12 after participants authorized and signed informed consent forms to participate in the study. All specimen donors were pathologically diagnosed with esophageal carcinoma, and treated at the pathology department of Tangshan people's hospital in Hebei province. The patients were from the Tangshan area, 136 cases were male, and 53 cases were female. The average age of subiects was 58 (range 40--76) years old. Subject were classified as follows according to clinical and pathological stages of esophagus carcinoma: 98 early-stage;, 63 middle -stage; and 28 late-stage. Tumor tissue differentiation was separated into 30 well-differentiated types, 104 moderately-differentiated types and 55 poorly-differentiated types. All fresh samples were stored at −80 °C prior to experiments.

HPV16/pBR322 and HPV18/pBR322 DNA plasmid containing the whole genome of HPV16 and HPV18, plasmid of beta-actin DNA containing part human housekeeping genes, and human embryonic kidney 293 (HEK293) cell line DNA were stored at −20 °C prior to experiments.

Methods {#Sec4}
=======

DNA extraction {#Sec5}
--------------

DNA was extracted from each tissue specimen (approximately 25 mg) using a QIAamp DNA mini kit (QIAGEN, Hilden, Germany) according to the manufacturer's instructions, and each sample DNA was eluted with approximately 50 μl sterilized distilled water. The concentration of each extracted DNA was detected and diluted to 100 ng/μl. DNA was stored at −20 °C.

Detection of specimen quality and HPV DNA {#Sec6}
-----------------------------------------

The quality of each tissue sample DNA was analyzed by PCR amplification using housekeeping gene β-actin primers \[[@CR20]\], HEK293 cell line DNA was used as a positive control, sterile water was used as a negative control to ensure the quality of specimens.

HPV DNA of each specimen was detected by PCR amplification using My09/11 primers for HPV L1 (My09: 5′-CGTCCMARRGGAWACTGATC-3′, MY11: 5′-GCMCAGGGWCATAAYAATGG-3′, PCR products 450 bp) \[[@CR16]\] and HPV16 E6-specific primers (forward: 5′- ACTGCGACGTGAGGTATATGAC-3′, reverse: 5′- TTGATGATCTGCAACAAGACATAC-3′, PCR products 320 bp), which were designed according to the GenBank-provided HPV16 gene sequences K02718.1 (<http://www.ncbi.nlm.nih.gov/nuccore/K02718>). Primers were synthezed by Sangon Biotech of Shanghai. The PCR products were resolved on a 1.0% agarose gel with Goldview I nuclear staining dye (BioTeke Corporation, Beijing, China) and observed with a UV transilluminator.

Total PCR reaction was performed using Ex Taq Polymerase kit (Takara Biotechnology Co., Ltd., Dalian, China) in a 25-μl volume containing 5 pmol each of the forward and reverse primers, 1 × Ex Buffer (MgCl~2~ free), 0.2 mM mixture deoxynucleoside triphosphate (dNTPs), 2.5 mM MgCl~2~, 1 U Ex Taq DNA polymerase, and 0.25 ng extracted DNA template and control template were added to the reaction system. The following cycling was used: 95 °C for 5 min, followed by 31 cycles of 95 °C for 30 s, 55 °C for 30 s, and 72 °C for 30 s. The final extension step was 72 °C for 5 min, and stored at 4 °C.

Reverse transcription (RT) {#Sec7}
--------------------------

Every sample RNA was extracted using the RNeasy Mini kit (Qiagen GmbH, Hilden, Germany) according to manufacturer's instruction. Reverse transcription (RT) was performed using M-MLV Reverse Transcriptase kit (BioTeke Corporation, Beijing, China) according to the manufacturer's protocol in a total volume of 20 μl, consisting of 9.2 μl RNase-free H2O, 4 μl of 5× first-strand buffer, 1.0 μl RNase inhibitor (40 U), 50 ng total RNA, 1 μl (dT)17-p3 (10 pmol primer: GACTCGAGTCGACATCGATTTTTTTTTTTTTTTTT), 0.5 μl dNTPs (0.2 mM), and 1 μl super script reverse transcriptase (200 U). The RNA reverse transcription was performed at 42 °C for 50 min and deactivated at 70 °C for 15 min, and the resulting product was stored at 4 °C.

To ensure mRNA quality of each tissue sample, human housekeeping gene GAPDH was detected using RT-PCR for verification of viral-cell fusion transcripts. The RT reactions were performed according to above, and the cDNA was stored at 4 °C. The PCR was conducted using a Takara Ex Taq Polymerase kit in a 20 μl reaction mixture containing 1X Ex buffer (MgCl~2~-free), 0.2 mM dNTPs, 2.5 mM MgCl~2~, 1 unit Ex Taq DNA polymerase, 5 pmol each GAPDH primer (forward, 5′-CATCACCATCTTCCAGGA-3′ and reverse, 5′-GTCTACCACCCTATTGCA-3′) and 2 μl cDNA template. The PCR cycling profile was as follows: 95 °C for 5 min; followed by 31 cycles of 95 °C for 30 s, 52 °C for 30 s and 72 °C for 30 s; followed by a final extension at 72 °C for 5 min; and storage at 4 °C.

The viral-cell fusion transcripts analysis {#Sec8}
------------------------------------------

The first PCR amplification was conducted according to Klaes et al. \[[@CR17]\] in a 20 μl volume using HPV16 E7-specific forward primers for p1--16 (5′-CGGACAGAGCCCATTACAAT-3′) and reverse primers for p3 (5′-GACTCGAGTCGACATCG-3′); the reaction system included 1 × Ex buffer, 2.5 mM MgCl~2~, 0.2 mM dNTPs, 5 pM primers, 2 μl cDNA, and 1 U Ex Taq DNA polymerase. The PCR cycle was as follows: 95 °C for 5 min, followed by 30 cycles at 95 °C for 1 min, 56 °C for 1 min, 72 °C for 3 min, and a final extension at 72 °C for 5 min, and stored at 4 °C.

Nested PCR was performed with identical conditions except for the annealing temperature at 67 °C with the following primers: HPV16 E7-specific forward primer p2--16 (5′-CTTTTTGTTGCAAGTGTGACTCTACG-3′) and reverse primer (dT)17-p3; 5 μl of the first round PCR product was used as template. To ensure specificity of these primers, HEK293 cell line DNA template was used as a negative control. The PCR products were resolved on a 1.0% agarose gel with Goldview I nuclear staining dye (BioTeke Corporation, Beijing, China) and observed with a UV transilluminator.

Cloning and sequence analysis for HPV16 integrated position in the human chromosome {#Sec9}
-----------------------------------------------------------------------------------

The final nested PCR products were cloned into pMD-18 T vector according to reference \[[@CR21]\], except the temperature of the target segment ligation to the pMD-18 T vector was changed to room temperature for 1 h. Then, commissioning Beijing Rui Bo Xing ke Biological Technology company to sequence. The sequencing results were blasted at NCBI (<https://blast.ncbi.nlm.nih.gov/Blast.cgi?PROGRAM=blastn&PAGE_TYPE=BlastSearch&LINK_LOC=blasthome>), and HPV16 integration sites were determined in human chromosome for every integration specimen, severally.

Statistical analysis {#Sec10}
--------------------

Statistical analysis was performed using Statistical Package for the Social Sciences (SPSS) version 13.0 software. *P* --value of less than 0.05 was considered as statistically significant.

Results {#Sec11}
=======

Detection of specimen quality and HPV DNA {#Sec12}
-----------------------------------------

290-bp PCR products of β-actin were detected in 189 DNA samples, this result indicated that these DNA samples were in high quality and could meet the requirements for further experiments.

168 specimens were detected HPV positive among 189 samples using MY09 / 11 primers (Fig. [1a](#Fig1){ref-type="fig"} and b). All HPV-positive samples were amplified using HPV16 E6 specific primer sets, and among them 76 specimens were HPV16 positive (Fig. [1a](#Fig1){ref-type="fig"} and b).Fig. 1aDetection of HPV DNA using MY09/11 primers in esophageal carcinoma samples. M was 100 bp DNA ladder; Neg was a negative control; lanes 1--7 were detection of HPV DNA in different esophageal carcinoma samples. HPV16 and 18 were positive controls with the HPV16/pBR322 and HPV18/pBR322 templates. **b** Detection of HPV16 DNA using HPV16 E6 specific primers in esophageal carcinoma samples. M was 100 bp DNA ladder; Neg was a negative control; lanes 1--7 were detection of HPV16 DNA in different esophageal carcinoma samples. HPV16 was a positive control with HPV16/pBR322 template; HPV18 was a specific control using HPV18/pBR322

HPV16 integration derived transcript in HPV16 E6 positive esophageal cancer samples {#Sec13}
-----------------------------------------------------------------------------------

HPV16 integrated positions were confirmed in the HPV16 positive samples. Approximately 600 bp PCR products were detected from nine HPV16 E6 positive samples by APOT. HPV16 E7 PCR products in nine samples were ligated into the pMD-18 T vector, and sequence analysis of HPV16 integration sites was performed. The sequence analysis showed that HPV16 E7 PCR products of nine samples were part of the HPV16 E7-E1 sequence, and compared with the HPV16 sequence provided in GenBank (K02718), the analysis results verified that integrated HPV16 E7 harbored one mutation from five samples of viral DNA (Fig. [2](#Fig2){ref-type="fig"}). Partial sequences from nine samples were similar to human chromosome sequences, as follows: three were similar to human chromosome 2 (Fig. [3](#Fig3){ref-type="fig"}a, b and c). One was similar to human chromosome 5 (Fig. [4](#Fig4){ref-type="fig"}), one was similar to human chromosome 6 (Fig. [5](#Fig5){ref-type="fig"}), two were similar to human chromosome 8 (Fig. [6](#Fig6){ref-type="fig"}a and b), and two were similar to human chromosome 17 (Fig. [7](#Fig7){ref-type="fig"}a and b).Fig. 2Alignment sequencing results compared with HPV16. Query 1--9: sequencing results for nine esophageal carcinoma specimens after PCR amplification with P2--16 E7-specific primers; Sbjct: part sequence of HPV 16E7-E1 in GenBank (K02718) Fig. 3Alignment sequencing results compared with human chromosome 2. **a-c**: Alignment sequencing results of three esophageal carcinoma specimens compared with human chromosome. Query: sequencing results for three esophageal carcinoma specimens after PCR amplification with P2--16 E7-specific primers; Sbjct: part sequence of human chromosome 2 Fig. 4Alignment sequencing results compared with human chromosome 5. Alignment sequencing results of one esophageal carcinoma specimens compared with human chromosome. Query: sequencing results for one esophageal carcinoma specimens after PCR amplification with P2--16 E7-specific primers; Sbjct: part sequence of human chromosome 5 Fig. 5Alignment sequencing results compared with human chromosome 6. Alignment sequencing results of one esophageal carcinoma specimens compared with human chromosome. Query: sequencing results for one esophageal carcinoma specimens after PCR amplification with P2--16 E7-specific primers; Sbjct: part sequence of human chromosome 6 Fig. 6Alignment sequencing results compared with human chromosome 8. **a**, **b**: Alignment sequencing results of two esophageal carcinoma specimens compared with human chromosome. Query: sequencing results for two esophageal carcinoma specimens after PCR amplification with P2--16 E7-specific primers; Sbjct: part sequence of human chromosome 8 Fig. 7Alignment sequencing results compared with human chromosome 17. **a,b**: Alignment sequencing results of two esophageal carcinoma specimens compared with human chromosome. Query: sequencing results for two esophageal carcinoma specimens after PCR amplification with P2--16 E7-specific primers; Sbjct: part sequence of human chromosome 17

The relationship between HPV16 integration and patient background {#Sec14}
-----------------------------------------------------------------

A total of fresh surgically resected tissue samples from 189 patients who were pathologically diagnosed with esophageal carcinoma were evaluated. The relationship between HPV16 integration and the patients' backgrounds are shown in Table [1](#Tab1){ref-type="table"}. Statistical analysis showed that HPV16 integration was not significantly correlated with gender, age, histological differentiation and pathological stage.Table 1Background of esophageal cancer patients and HPV16 integrationBackgroundHPV16 positive(*n* = 79)Samples (*n* = 189)IntegratedWithout*X* ^2^*P* ^a^integratedsex0.06\>0.05 male55136748 female2153219age (year old)1.38\>0.05  ≤ 451841117 46--642870325  ≥ 653078525differentiated type0.09\>0.05 well differentiated1130110 moderately differentiated49104643 poorly differentiated1655214pathological stages2.99\>0.05 early stage2598223 middle stage4063436 late stage112838Total76189967^a^Notice: There were no statistically significant difference (*P*\>0.05)

Discussion {#Sec15}
==========

High-risk HPV infection (such as HPV types16, HPV18, HPV31, HPV33, HPV35, HPV39, HPV45, HPV51, HPV52, HPV56, HPV58 and HPV59) have been identified as causative agents in cervix cancers \[[@CR22], [@CR23]\]. However, HPV has not been determined as to be a pathogenic factor for esophageal cancer occurrence thus far in highly prevalent regions \[[@CR24], [@CR25]\].

In the present study, HPV DNA from 189 patient tissue samples with pathologic diagnosis of esophageal carcinoma were examined, and a high prevalence was found (approximately 89% HPV DNA positive rate), and the HPV16 positive rate was 40.2%; Mehryar et al. \[[@CR26]\] study showed that the prevalence of HPV types 16 and 18 was 40.40% and 47.47% in esophageal carcinoma for Tangshan, Hebei province, China, respectively, Dong et al. \[[@CR7]\] study showed that Six HPV genotypes (HPV6, HPV16, HPV33, HPV39, HPV51, and HPV82) were present in at least 51.7% of the esophagealcarcinoma tissues, and combined with other studies \[[@CR8]--[@CR11]\], these findings indicate that HPV infection may be a pathogenic factor for esophageal cancers.

HPV16 integration was discovered in esophageal cancer cells from nine patient specimens, and HPV16 was found to be integrated into chromosomes 2, 5, 6, 8 and 17. With the integration of HPV18 in EC109 cells, these results indicate that HPV randomly integrates into the host chromosome and that the HPV viral genome is cleaved at the E1 and E2 ORFs for integration. Moreover, the E2 gene serves as a pivotal modulator for E6 and E7 gene expression in the viral life cycle. In many HPV-infected patients, HPV E2 restrains E6 and E7 gene transcription, which aids in the regulation of cellular proliferation \[[@CR27]\]. Cleaving the E2 gene increased HPV E6 and E7 gene expression, which disrupts the cell cycle and leads to aberrant proliferation \[[@CR28]--[@CR30]\]. HPV E6 and E7 genes usually integrate into the host cell genome and require longer incubation periods for viral DNA replication and recombination to produce a variety of genetic changes in the viral and human genome. The expression levels of E6 and E7 simultaneously increased, which resulted in human chromosomal instability and the development of malignant tumors \[[@CR18]\]. On the other hand, among nine integrated HPV16 specimens, three patient samples were in the late stage, including two females and one male, four patient samples from males were in the middle stage, and two patient samples from males were in the early stage; one was a well-differentiated sample, and six were moderately-differentiated samples, and two were poorly differentiated samples. Nine patient samples seem too small to be able to indicate that HPV16 integration is related to patient background (including gender, age, degree of differentiation, and pathological stages) and supports the assumption of preferred selective outgrowth of HPV-infected cells in preneoplastic lesions that express integrated viral oncogenes E6 and E7. The sequencing results showed one mutation for five DNA samples compared with the GenBank-provided HPV16 gene sequences of K02718.1 (<http://www.ncbi.nlm.nih.gov/nuccore/K02718>). This phenomenon may be different for local epidemic strains of HPV16. Next we will be to detect other HPV types infection and integration sites.

Conclusions {#Sec16}
===========

In this study, 76 specimens were HPV16 positive in 189 esophageal carcinoma samples, this result suggested that a high prevalence of HPV16 plays an etiological role in the development of esophageal cancer. The integration of HPV16 into host cell chromosomes suggests that persistent HPV infection is key for esophageal epithelial cell malignant transformation and carcinogenesis. However, HPV infection may be one of multiple risk factors of esophageal cancer. Further work is needed to elucidate the underlying mechanism, other types of HPV integration sites, the genetic changes associated with HPV infection, and the molecular mechanism of esophageal cancer occurrence.

APOT

:   Amplification of papillomavirus oncogene transcripts.

EC

:   Esophageal carcinoma

HPV

:   Human papillomavirus

PCR

:   Polymerase chain reaction

Not applicable.

Funding {#FPar1}
=======

This study supported by the project of Science and technology for overseas scholars in Hebei Province (No.CY201620), the project of Hebei education department (No.ZD2016003), the Project of North China University Science and Technology (No. sp201506), Beijing Natural Science Foundation (No. 5162003).

Availability of data and materials {#FPar2}
==================================

Data sharing not applicable to this article as no datasets were generated or analysed during the current study.

Shuying Li, Ke Zhang, and Jintao Li, designed the study, performed the majority of the experiments, wrote the manuscript, and contributed equally to this work; Haie Shen, Ning Li, Suxian Yang, were samples collection, and performed some experiments; Zhanjun Liu, participated in the design of the study, and performed the statistical analysis. All authors read and approved the final manuscript.

Ethics approval and consent to participate {#FPar3}
==========================================

Before the samples were taken, participants authorized and signed informed consent forms to participate in the study. Ethical approval of this study was obtained from the Ethics Committee of the North China University of Science and Technology.

Consent for publication {#FPar4}
=======================

Not applicable.

Competing interests {#FPar5}
===================

The authors report no conflicts of interest.

Publisher's Note {#FPar6}
================

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
